Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AsiDNA with PARP Inhibitors in Relapsed Ovarian Cancer (REVOCAN)
NCT04826198Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of asidna in ovarian cancer, sponsored by Gustave Roussy. Started Oct 2020; status: terminated.
02
Drugs
asidna
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04826198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826198.